NMPA approves Pusintin® (biosimilar bevacizumab)

Dec 1, 2021

Tot Biopharm announced that China’s NMPA has approved Pusintin® (biosimilar bevacizumab) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer and patients with metastatic colorectal cancer.

Print Page Mail Article